Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Change in Accured Expenses (2019 - 2025)

Historic Change in Accured Expenses for Allogene Therapeutics (ALLO) over the last 7 years, with Q3 2025 value amounting to $1.1 million.

  • Allogene Therapeutics' Change in Accured Expenses fell 5704.11% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $478000.0, marking a year-over-year increase of 11239.63%. This contributed to the annual value of -$1.3 million for FY2024, which is 8150.37% up from last year.
  • Per Allogene Therapeutics' latest filing, its Change in Accured Expenses stood at $1.1 million for Q3 2025, which was down 5704.11% from $1.7 million recorded in Q2 2025.
  • In the past 5 years, Allogene Therapeutics' Change in Accured Expenses registered a high of $8.9 million during Q3 2021, and its lowest value of -$12.7 million during Q3 2023.
  • Its 5-year average for Change in Accured Expenses is -$267684.2, with a median of $1.1 million in 2025.
  • Examining YoY changes over the last 5 years, Allogene Therapeutics' Change in Accured Expenses showed a top increase of 90699.3% in 2024 and a maximum decrease of 114050.63% in 2024.
  • Quarter analysis of 5 years shows Allogene Therapeutics' Change in Accured Expenses stood at -$2.8 million in 2021, then soared by 213.33% to $3.1 million in 2022, then tumbled by 90.88% to $286000.0 in 2023, then skyrocketed by 906.99% to $2.9 million in 2024, then tumbled by 62.29% to $1.1 million in 2025.
  • Its last three reported values are $1.1 million in Q3 2025, $1.7 million for Q2 2025, and -$5.2 million during Q1 2025.